CASPOFUNGIN POWDER FOR INJECTION 50 MG — DIN 02448815
CASPOFUNGIN (CASPOFUNGIN ACETATE) : 50 MG · TEVA CANADA LIMITED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is CASPOFUNGIN POWDER FOR INJECTION?
CASPOFUNGIN POWDER FOR INJECTION 50 MG contains CASPOFUNGIN (CASPOFUNGIN ACETATE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02448815, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 15-Apr-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CASPOFUNGIN POWDER FOR INJECTION used for?
Caspofungin Powder for Injection is indicated for use in adults and children 12 months and older for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. Treatment of Invasive Candidiasis including candidemia, intra-abdominal abscesses, peritonitis and pleural space infections. Treatment of Esophageal Candidiasis. Treatment of Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Caspofungin cost around the world?
Caspofungin is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a ex-factory (classe H); Romania publishes a max producer price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 18 | 18 | ZAR███.██ |
| Romania | max producer price | 13 | 15 | RON███.██ |
| Italy | ex-factory (classe H) | 6 | 14 | EUR███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Saudi Arabia | public | 10 | 12 | SAR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
74 pack listings across 62 brand entries and 6 price bases, refreshed 03 Sep 2026. Ranges span every Caspofungin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Caspofungin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Caspofungin, across 12 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 2 | 2 | CASPOFUNGIN FOR INJECTION | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 2 | 2 | CASPOFUNGIN FOR INJECTION | Sourceable in Canada |
| MERCK CANADA INC | 2 | 1 | CANCIDAS | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 0 | CASPOFUNGIN ACETATE FOR INJECTION | No marketed DIN |
| STERIMAX INC | 2 | 0 | CASPOFUNGIN ACETATE FOR INJECTION | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | CASPOFUNGIN POWDER FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Caspofungin |
|---|---|
| ATC code | J02AX04 |
| AHFS class | 68:30.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02448815 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2448815 |
| Brand name | CASPOFUNGIN POWDER FOR INJECTION |
| Generic / active ingredient | CASPOFUNGIN (CASPOFUNGIN ACETATE) : 50 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | J02AX04 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J02AX |
| Current status | CANCELLED PRE MARKET |
| Status date | 15-Apr-2025 |
| Original market date | 2016-03-10 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Caspofungin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by FRESENIUS KABI CANADA LTD, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CANCIDAS | 70 MG | POWDER FOR SOLUTION | MERCK CANADA INC | MARKETED | 02244266 |
| CASPOFUNGIN FOR INJECTION | 50 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | 02460947 |
| CASPOFUNGIN FOR INJECTION | 70 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02486997 |
| CASPOFUNGIN FOR INJECTION | 50 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02486989 |
| CASPOFUNGIN FOR INJECTION | 70 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | 02460955 |
| CANCIDAS | 50 MG | POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | 02244265 |
| CASPOFUNGIN ACETATE FOR INJECTION | 50 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | 02456133 |
| CASPOFUNGIN ACETATE FOR INJECTION | 70 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | 02456125 |
| CASPOFUNGIN ACETATE FOR INJECTION | 70 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02389207 |
| CASPOFUNGIN ACETATE FOR INJECTION | 50 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02389193 |
2 · Same class — other molecules in ATC J02AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Micafungin | MICAFUNGIN FOR INJECTION · MICAFUNGIN SODIUM FOR INJECTION · MYCAMINE | 10 | 6 | Yes |
| Caspofungin | CANCIDAS · CASPOFUNGIN ACETATE FOR INJECTION · CASPOFUNGIN FOR INJECTION · CASPOFUNGIN POWDER FOR INJECTION | 12 | 5 | Yes |
| Anidulafungin | ERAXIS · GD-ANIDULAFUNGIN | 3 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J02AC | Fluconazole · Isavuconazole · Itraconazole · Posaconazole · Voriconazole | 115 | 54 |
| J02AA | Amphotericin B | 7 | 2 |
| J02AB | Ketoconazole | 5 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.